Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by GoldenInvestoron Nov 15, 2024 9:28am
97 Views
Post# 36314624

Fr GUD to great : more help for ADHD

Fr GUD to great : more help for ADHDAcross our territories ADHD is huge and growing across kids and adults. Big in canada, bigger in LATAM

great new tool in our tool chest.

https://nasenjournals.onlinelibrary.wiley.com/doi/full/10.1111/1471-3802.12642


Although the estimated prevalence of ADHD in the school population is 5%, various studies carried out in Latin America have obtained higher figures. This descriptive-cross-sectional research analysed the prevalence of ADHD symptomatology in a random and probabilistic sample of 1535 schoolchildren from Cuenca-Ecuador (aged from 72 to 164 months, 51.3% were female and 50% attended public schools). IQ was evaluated using the Raven's Progressive Matrices Test. The ADHD symptomatology was evaluated using the short version of Conners-3. Descriptive statistics, chisquares and prevalence data were calculated. We found a total prevalence of ADHD symptomatology of 20.3%. A higher prevalence of ADHD symptomatology was reported among girls compared to boys; and in public schools (compared to private schools). These findings may reflect a higher occurrence of ADHD in vulnerable populations that tend to be less well cared for. Although the results do not come from complete individual clinical evaluations, the representativeness of the sample and the simultaneous presence of scores above the cut-off points in the home and school contexts show a worrying situation that should be taken into account by agents responsible for the design of public health and education policies.
<< Previous
Bullboard Posts
Next >>